Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping.
James C CoonsJames M StevensonAmi PatelA J Conrad SmithLinda PrebehallaPhilip E EmpeyPublished in: Journal of cardiovascular pharmacology and therapeutics (2022)
Bleeding is common in post-PCI patients on antiplatelet therapy. Patients on high potency agents had higher bleeding risk in the population at-large and in non-carriers of CYP2C19 no function alleles. Genotype-guided antiplatelet de-escalation should be further explored in prospective studies.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- end stage renal disease
- atrial fibrillation
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- coronary artery disease
- high throughput
- gene expression
- heart failure
- acute myocardial infarction
- patient reported outcomes
- open label
- adipose tissue
- genome wide
- weight loss
- insulin resistance
- study protocol
- double blind
- case control